Coherus Oncology, Inc. (NASDAQ:CHRS) Given Consensus Rating of “Hold” by Brokerages

Shares of Coherus Oncology, Inc. (NASDAQ:CHRS) have earned an average recommendation of “Hold” from the five brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $5.5125.

Several analysts recently issued reports on the stock. Oppenheimer assumed coverage on shares of Coherus Oncology in a report on Thursday. They issued an “outperform” rating and a $10.00 price objective on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Coherus Oncology in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th.

Coherus Oncology Trading Up 10.7%

Shares of Coherus Oncology stock opened at $2.28 on Thursday. The stock has a 50 day moving average of $1.42 and a 200 day moving average of $1.35. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.23 and a current ratio of 1.24. The firm has a market capitalization of $275.58 million, a price-to-earnings ratio of 1.71 and a beta of 0.96. Coherus Oncology has a fifty-two week low of $0.71 and a fifty-two week high of $2.30.

Coherus Oncology (NASDAQ:CHRS) last announced its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.01. The business had revenue of $11.57 million during the quarter, compared to analyst estimates of $13.41 million. As a group, research analysts predict that Coherus Oncology will post -1.05 earnings per share for the current year.

Institutional Investors Weigh In On Coherus Oncology

A number of institutional investors have recently modified their holdings of the company. Quarry LP purchased a new stake in shares of Coherus Oncology in the 3rd quarter valued at $26,000. Voya Investment Management LLC acquired a new position in Coherus Oncology in the 3rd quarter valued at about $28,000. International Assets Investment Management LLC purchased a new stake in Coherus Oncology during the second quarter worth about $33,000. Corient Private Wealth LLC lifted its position in shares of Coherus Oncology by 20.0% during the second quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 10,000 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of Coherus Oncology by 108.2% during the third quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 13,832 shares in the last quarter. 72.82% of the stock is owned by institutional investors and hedge funds.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.